21Shares Pursues SEC Approval for Injective ETF Amid Surging Institutional Demand

Institutional crypto adoption hits new milestone as 21Shares files for groundbreaking Injective ETF

The crypto asset management giant just dropped its latest regulatory filing—and it's targeting one of the most promising Layer 1 protocols in the space. With institutional demand for digital assets reaching fever pitch, 21Shares is positioning itself at the forefront of the next wave of crypto investment products.

Why Injective Matters

This isn't just another crypto ETF application. Injective's specialized focus on decentralized finance protocols and cross-chain trading infrastructure makes it uniquely positioned for institutional adoption. The protocol's recent performance and growing developer ecosystem have caught the attention of serious players looking beyond Bitcoin and Ethereum.

The Institutional Floodgates Are Opening

Major financial institutions that once dismissed crypto are now scrambling for exposure. From hedge funds to family offices, the demand for regulated crypto products is exploding. 21Shares' move signals that the industry expects this trend to accelerate—regardless of what traditional finance skeptics might claim about 'digital tulips.'

SEC's Growing Crypto Dilemma

While the regulatory path remains challenging, the pressure is mounting on the SEC to approve more sophisticated crypto products. Each successful filing creates precedent for the next, building momentum that even the most cautious regulators will find difficult to ignore.

Because when Wall Street wants something badly enough, regulations tend to become surprisingly flexible.

TLDR

• 21Shares has officially filed a proposal with the SEC for a spot Injective ETF.
• The ETF aims to offer investors direct exposure to INJ through physical token custody.
• Injective’s official X account shared the ETF filing, increasing market visibility and interest.
• INJ price remained stable above $8.00 after briefly dipping to $7.80 earlier in October.
• The Injective blockchain continues expanding through strategic partnerships and ecosystem development.

21Shares has officially filed with the SEC for a new spot Injective ETF, aiming to offer direct exposure to INJ. The filing arrives as Injective continues gaining traction in institutional and DeFi markets, backed by strong infrastructure. INJ price hovered near $8.75 following the news, as bulls held firm despite recent market pressure.

21Shares Advances Injective ETF Plans

21Shares submitted its proposed Injective ETF to the U.S. Securities and Exchange Commission early this week. The ETF will hold physical INJ tokens in cold storage to provide direct price exposure. This structure aligns with the approved spot ETFs for Bitcoin and Ethereum.

🚨 BREAKING: 21Shares just filed for a new $INJ ETF.

This is a major signal of growing institutional interest, making $INJ one of the few digital assets with multiple ETF products in progress.@21Shares is among the world’s largest exchange traded product issuers. pic.twitter.com/xjWSZJVmsT

— Injective 🥷 (@injective) October 20, 2025

The company shared the news on Injective’s official X account, boosting market visibility and token sentiment. Market watchers noted that the Injective ETF represents rising interest in LAYER 1 blockchains. Previously, Canary Capital had filed for a similar INJ ETF in July.

The 21Shares Injective ETF marks another step toward institutional integration of DeFi-focused digital assets. “This ETF will offer exposure to INJ via secure cold storage,” stated the official filing. With SEC reviews underway, industry participants anticipate broader access to Injective via regulated investment vehicles.

Injective’s Market Position Strengthens

Injective, a high-performance Layer 1 blockchain, is gaining attention for its institutional partnerships and rapid technical development. The network processes over 25,000 transactions per second using delegated proof-of-stake (DPoS) consensus. This architecture supports scalability and low-latency trading for DeFi markets.

Its roadmap includes native ethereum Virtual Machine compatibility and pre-IPO market tools, supported by strong partners like Google Cloud and BitGo. Recent developments include the first meeting of the Injective Council, focused on advancing governance and strategic goals. The Injective ETF filing aligns with these broader expansion efforts.

Token liquidity and platform adoption continue to rise amid increased DeFi and real-world asset integration. The Injective ETF further enhances its standing among top blockchain networks. As institutional players explore this asset, long-term demand for INJ could increase.

INJ Price Holds Amid ETF Buzz

INJ traded around $8.75 as of Monday, showing stability despite broader crypto volatility and recent dips. Prices had dropped to $7.80 on October 17 but recovered as bullish interest returned. Traders aim to maintain support above $8.00, with positive momentum from ETF-related news.

INJ remains down from its March high of $52.75 and December peak near $35. Yet, Optimism surrounds ETF-driven accumulation and treasury strategies. For example, Pineapple Financial recently allocated $100 million in digital assets, including INJ.

While the Injective ETF news hasn’t sparked a major rally, sentiment remains strong across crypto markets. The SEC’s decisions on crypto ETFs could shape short-term price movements. Nevertheless, the Injective ETF proposal reinforces growing institutional confidence in the asset.